Rabies Diagnostics Market Size, Share, Growth, Trends and Forecast Report, 2019 to 2025

13/ago/2019 16:07:47 susan hill Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

The global rabies diagnostics market size is expected to reach USD 2.03 billion by 2025 and is projected to expand at a CAGR of 4.1% during the forecast period, according to a new report by Grand View Research, Inc. Development of various diagnostic assays ranging from detection of virus presence to final confirmation of infection helps launch effective disease control programs. This factor is anticipated to drive the market growth. These assays aid in defining epidemiologic patterns of the disease and thereby deliver appropriate information for designing the control and eradication programs. These programs have boosted the market growth by increasing the rate at which testing kits are adopted.

For example, in June 2018, the World Health Organization (WHO), the World Organization for Animal Health (OIE), the Global Alliance for Rabies Control (GARC), and the Food and Agriculture Organization of the United Nations (FAO) entered into a partnership for a plan, The United Against Rabies Collaboration. This plan aims for rabies prevention and management and empowering the under-served populations in afflicted countries.

Furthermore, the state and public health officials of the Department of Public Health and Human Services (DPHHS) along with the Department of Livestock of Montana, U.S., deal with awareness pertaining to the risk of virus exposure. They are engaged in training the population about various aspects of disease management including prevention, detection, and available treatment modes. Such initiatives are projected to create growth opportunities for the rabies diagnostics market during the forecast period.

Further key findings from the report suggest:

  • Fluorescent Antibody Test (FAT) held the largest market share in terms of revenue owing to the high usage and recommendation by the WHO. Great specificity, as compare to other conventional tests such as serology and histology tests bodes well for the adoption of these tests
  • Amplification methods are expected to supplant a major portion of conventional methods, primarily due to several advantages associated with the usage
  • Currently, major products deploy ELISA/immunohistochemistry techniques, resulting into a larger revenue share of this segment
  • High prevalence of the disease in India and China coupled with growing government support has contributed to the dominance of Asia market over other regions
  • Since, most of the countries in Europe are designated as rabies free jurisdictions, the Europe market is anticipated to grow at the slowest pace over the forecast period
  • Bio-Rad Laboratories, Inc.; Merck KGaA; Aviva Systems Biology Corporation; and Creative Diagnostics are some of the key entities in the rabies testing market. The companies engage in developing products for rabies eradication programs.

Grand View Research has segmented the global rabies diagnostics market on the basis of diagnostic method, technology, and region:

Rabies Diagnostics Diagnostic Method Outlook (Revenue, USD Million, 2014 - 2025)

  • Fluorescent antibody test (FAT)
  • Immunohistochemical test
  • Amplification methods
  • Histologic examination
  • Serology tests

Rabies Diagnostics Technology Outlook (Revenue, USD Million, 2014 - 2025)

  • ELISA/Immunohistochemistry
  • Chromatography techniques
  • PCR
  • Others

Rabies Diagnostics Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Spain
  • Asia Pacific
    • India
    • China
    • Indonesia
  • Latin America
    • Brazil
  • Middle East & Africa
    • South Africa

Access full research report on global rabies diagnostics market: 

https://www.grandviewresearch.com/industry-analysis/rabies-diagnostics-market

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl